{"filings":[{"id":67921,"accession_number":"0001720580-26-000036","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2026-05-13T20:04:12+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio Q1 net loss $20.2M; prula-cel Phase 1 data expected mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.2M ($1.88/share) vs $28.2M ($4.96/share) in Q1 2025; R&D expenses down to $17.5M.","Cash, cash equivalents and ST investments $137.6M at March 31, 2026; expected runway into H2 2027.","Phase 1 prula-cel update in mid-2026 with at least 20 LN/SLE patients, min 6 months follow-up.","FDA interaction in Q2 2026 to inform potential pivotal trial design; plan to start pivotal program in H2 2026.","Regulatory filing for ADI-212 in mCRPC planned for Q3 2026; Phase 1 enrollment expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94976,"accession_number":"0001720580-26-000023","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Adicet Bio swaps 250K shares for pre-funded warrant at $0.0001 strike to RA Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RA Capital exchanged 250,000 common shares for a pre-funded warrant to acquire 250,000 shares at $0.0001 per share.","Warrant is exercisable from issuance via cashless exercise; includes a 9.99% beneficial ownership blocker (can be raised to 19.99%).","Issued under Section 3(a)(9) exemption; no new cash proceeds raised and no change in total outstanding shares.","Pre-funded warrant effectively equivalent to common stock upon exercise due to nominal exercise price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107732,"accession_number":"0001720580-26-000006","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio reports Q4 2025 net loss $30.5M; Phase 1 prula-cel enrollment momentum; cash $158.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025: $30.5M ($2.94 per diluted share) compared to $28.7M ($5.06) in Q4 2024.","Full-year 2025 net loss $116.8M ($16.95 per share) vs $117.1M ($21.33) in 2024.","Cash, equivalents & investments $158.5M at Dec 31, 2025; expected to fund ops into H2 2027.","Phase 1 prula-cel autoimmune enrollment ahead; next update H1 2026; pivotal study H2 2026 subject to FDA.","ADI-212 regulatory filing for mCRPC expected Q3 2026; Phase 1 enrollment Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107731,"accession_number":"0001193125-26-005486","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adicet Bio reports prula-cel Phase 1 enrollment doubles to 20+ patients; FDA allows outpatient dosing for SLE/LN","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment in prula-cel autoimmune Phase 1 program doubled to over 20 patients as of Dec 31, 2025.","FDA alignment achieved to allow outpatient dosing of SLE and lupus nephritis patients in ongoing and future trials.","Plans to request FDA meeting in Q2 2026 to discuss potential Phase 2 pivotal trial design for prula-cel.","Regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer expected in H1 2026.","Cash runway extended into H2 2027 following $74.8M net proceeds from October 2025 equity offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124107,"accession_number":"0001193125-25-332343","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-12-29T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Adicet Bio announces 1-for-16 reverse stock split effective Dec 30, 2025; reduces shares from ~153.3M to ~9.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-16 reverse split within previously authorized 1:5 to 1:30 range; effective 12:01 a.m. ET Dec 30, 2025.","Outstanding shares drop from ~153.3 million to ~9.6 million; authorized shares unchanged at 300 million.","Purpose: regain compliance with Nasdaq minimum bid price requirement for continued listing.","No fractional shares issued; holders receive cash in lieu; proportional adjustments to equity plans and warrants.","CUSIP number changes to 007002207; trading symbol remains ACET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124106,"accession_number":"0001193125-25-326784","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Adicet Bio stockholders approve reverse stock split (1:5 to 1:30)","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal passed with 111,115,503 votes for, 2,752,862 against, and 117,502 abstentions.","Board will set exact split ratio within the approved range at its discretion.","Special meeting held on December 19, 2025; no other proposals were considered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124105,"accession_number":"0001193125-25-266860","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio Q3 net loss $26.9M; positive ADI-001 Phase 1 data in LN/SLE; cash runway extended to H2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive Phase 1 ADI-001 data in 7 LN/SLE patients: SLEDAI-2K reductions, improved renal function, no Grade 2+ CRS or ICANS.","Plans FDA meeting Q1 2026 for potentially pivotal trial; initiation targeted Q2 2026.","Q3 2025 net loss $26.9M ($0.29 loss per share); R&D $22.9M, G&A $5.1M; cash $103.1M as of Sep 30.","Raised $74.8M net proceeds in October 2025 registered direct offering; cash runway into H2 2027.","ADI-212 regulatory filing for mCRPC on track Q1 2026; initial data expected H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124104,"accession_number":"0001193125-25-233427","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Adicet Bio granted 180-day Nasdaq extension; transferred to Capital Market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extension until April 6, 2026 to regain $1.00 minimum bid price; transferred to Nasdaq Capital Market effective Oct 9, 2025.","Company may consider reverse stock split to meet bid price requirement; if not regained, Nasdaq will issue delisting notice.","Previous 180-day compliance period ended Oct 6, 2025; extension granted Oct 7, 2025.","No immediate impact on common stock listing; ACET continues trading under symbol ACET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124103,"accession_number":"0001193125-25-232558","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Adicet Bio raises ~$74.8M in underwritten offering of 70M shares + 10M pre-funded warrants at $1.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 70,001,000 common shares at $1.00/share and pre-funded warrants for 10M shares at $0.9999 each.","Net proceeds estimated at ~$74.8M after 6% underwriting discount and expenses.","Expected to close on October 8, 2025; Jefferies and Guggenheim lead underwriters.","Pre-funded warrants have $0.0001 exercise price, cashless exercise, 9.99% beneficial ownership limitation.","Offering made under existing Form S-3 shelf registration (File No. 333-285609)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124102,"accession_number":"0001193125-25-232539","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-10-07T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"Adicet Bio: 100% renal response in Phase 1 ADI-001 lupus nephritis; plans FDA meeting Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Seven patients (5 LN, 2 SLE) dosed; follow-up 2–9 months as of Aug 31, 2025 cut-off.","All 5 LN patients achieved renal response: 3 complete, 2 partial; all ongoing; 3 also DORIS remission.","No serious AEs, no ICANS; only Grade 1 CRS (2 patients) and 1 Grade 1 infection; outpatient potential.","All patients discontinued immunosuppressants; discontinued or tapered corticosteroids to physiological levels.","Plans to request FDA meeting in Q1 2026 for pivotal Phase 2 trial design; enrollment continues until study opens."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140763,"accession_number":"0000950170-25-104969","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio Q2 net loss $31.2M; discontinues ADI-270, cuts workforce 30%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $31.2M ($0.34/sh) vs $29.9M ($0.33/sh) in Q2 2024; R&D spending rose to $28.4M.","Cash $125.0M as of June 30, 2025, down from $176.3M at year-end 2024; runway into Q4 2026.","Discontinued ADI-270 for ccRCC; workforce reduced ~30% to extend cash runway.","Prioritizing ADI-212 (PSMA, prostate cancer); IND filing expected Q1 2026, data 2H 2026.","Phase 1 ADI-001 autoimmune trial expanded to IIM, SPS, AAV; preliminary data expected 2H 2025."],"consensus_eps_estimate":-4.966,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140762,"accession_number":"0000950170-25-097881","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["2.05","8.01","9.01"],"status":"ready","headline":"Adicet Bio reduces workforce 30%, discontinues ADI-270, extends cash runway into Q4 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~30%; expects $2.3M in severance costs in Q3 2025.","Discontinued ADI-270 for ccRCC; focus shifts to ADI-001 (autoimmune) and ADI-212 (PSMA).","ADI-270 Phase 1 data: 100% disease control rate, 20% response rate; no cytokine release syndrome.","Restructuring and program cuts expected to extend cash runway into Q4 2026.","ADI-212 is an optimized next-generation gene-edited, cytokine-armored CAR T targeting PSMA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158505,"accession_number":"0000950170-25-086120","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Adicet Bio annual meeting elects directors, approves exec compensation, ratifies KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Chen Schor and Katie Peng elected as Class I directors for three-year terms; Chen received 32.38M votes for, 7.57M withheld.","Non-binding advisory vote on named executive officer compensation approved with 31.21M for, 8.62M against.","Ratification of KPMG as independent auditor for FY2025 approved with 58.53M for.","Broker non-votes of 18.90M were present on director election and advisory compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158504,"accession_number":"0000950170-25-064423","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio reports Q1 net loss $28.2M ($0.31/sh); cash $150.4M; expects data readouts in 2H 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.2M ($0.31 per share) vs $28.0M loss in Q1 2024; R&D spending $22.8M.","Cash $150.4M as of Mar 31, 2025; company expects to fund operations into 2H 2026.","Phase 1 trial of ADI-001 in autoimmune diseases expanded to LN/SLE; preliminary data expected 2H 2025.","Phase 1 trial of ADI-270 in metastatic/advanced ccRCC ongoing; preliminary data expected 2H 2025.","Michael Grissinger appointed to board; FDA granted Fast Track for ADI-001 in SLE and SSc."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158503,"accession_number":"0000950170-25-054995","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Adicet Bio appoints Michael Grissinger to Board; Carl Gordon resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carl L. Gordon resigned from Board and Compensation Committee effective April 17, 2025; no disagreement with management.","Michael Grissinger appointed to Board and Compensation Committee, effective April 17, 2025, as Class II director until 2026 annual meeting.","Grissinger received option to purchase 70,200 shares at April 17 closing price, vesting over 36 months.","Grissinger brings 40+ years pharma experience, including 20+ years at Johnson & Johnson leading immunology licensing and M&A.","He also serves on boards of Aprea Therapeutics (APRE) and three private biotechs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158502,"accession_number":"0000950170-25-053238","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Adicet Bio receives Nasdaq delisting notice for bid price below $1; cure period to Oct 6, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on April 7, 2025 for non-compliance with minimum bid price rule (closing bid <$1 for 30 consecutive days).","Initial compliance period ends October 6, 2025; must close at or above $1 for at least 10 consecutive days to regain compliance.","If not cured, may seek additional 180-day period by transferring to Nasdaq Capital Market and meeting other listing standards.","Company considering reverse stock split as a potential cure; no assurance of regaining compliance or maintaining listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176891,"accession_number":"0000950170-25-034580","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio Q4 net loss $0.32/share, cash $176.3M; expects ADI-001 LN data in 1H25","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net loss $28.7M ($0.32/share) vs. $29.5M ($0.69/share) in Q4 2023; full year net loss $117.1M.","Cash, cash equivalents and short-term investments $176.3M as of Dec 31, 2024; expected to fund ops into 2H26.","Phase 1 trial of ADI-001 in autoimmune diseases: LN patient preliminary data expected 1H25; enrollment for SLE, SSc, IIM, SPS to start 2Q25.","ADI-270 Phase 1 in ccRCC: preliminary data expected 1H25; first patient dosed Dec 2024.","Received FDA Fast Track Designation for ADI-001 in refractory SLE with extrarenal involvement and SSc (Feb 2025)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176890,"accession_number":"0000950170-25-014153","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2025-02-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Adicet Bio reports 3 patients each enrolled in Phase 1 trials of ADI-001 LN and ADI-270 ccRCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADI-001 LN Phase 1: 3 patients enrolled as of Feb 2025; first dosed Nov 2024; ~12 sites activated; preliminary data due H1 2025.","ADI-001 additional autoimmune indications: Phase 1 enrollment to start Q1 2025 for SLE, systemic sclerosis, IIM, stiff person syndrome; preliminary data H2 2025.","ADI-270 ccRCC Phase 1: 3 patients enrolled; first dosed Dec 2024; ~7 sites activated; preliminary data expected H1 2025.","ANCA-associated vasculitis enrollment planned for H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193704,"accession_number":"0000950170-24-138419","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adicet Bio doses first patient in Phase 1 trial of ADI-270 for advanced clear cell renal cell carcinoma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in Phase 1 trial of ADI-270, an allogeneic gamma delta 1 CAR T cell therapy, for metastatic/advanced ccRCC.","Phase 1 trial is multicenter, open-label, monotherapy; starting dose 3E8 CAR+ cells with option for second dose.","Company expects to report preliminary Phase 1 clinical data in the first half of 2025.","Preclinical data showed ADI-270 demonstrated tumor infiltration, resistance to immunosuppressive TME, and potent CAR/innate activity.","ccRCC is the most common kidney cancer; patients with advanced disease have limited treatment options and high unmet need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193703,"accession_number":"0000950170-24-131609","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Adicet Bio terminates loan agreement with Banc of California, repays ~$10,000","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Payoff letter executed Nov 27, 2024; outstanding obligations repaid for approx. $10,000.","Loan and Security Agreement dated April 28, 2020 fully terminated; no penalty paid.","Company established cash collateral accounts and pledge agreements for ancillary services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193702,"accession_number":"0000950170-24-127927","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adicet opens ADI-270 Phase 1 enrollment in ccRCC, doses first lupus nephritis patient with ADI-001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enrollment opened for Phase 1 trial of ADI-270 in metastatic/advanced clear cell renal cell carcinoma; preliminary data expected 1H25.","First lupus nephritis patient dosed in Phase 1 trial of ADI-001; preliminary clinical data in LN anticipated 1H25.","ADI-001 received FDA Fast Track Designation for relapsed/refractory class III or IV lupus nephritis.","Company expects to begin enrollment in SLE, SSc, IIM, SPS in 1Q25 and AAV in 2H25.","ADI-270 is the first gamma delta CAR T cell therapy for solid tumors to enter clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193701,"accession_number":"0000950170-24-127560","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Adicet Bio amends loan agreement to remove Adicet Shanghai shares from collateral, allow $500K transfers","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Eighth Amendment to loan with Banc of California (formerly Pacific Western Bank) dated Nov 8, 2024.","Equity interests in Adicet Shanghai removed from pledged collateral; no security interest on those shares.","Permitted investment threshold for cash transfers to Adicet Shanghai increased to $500,000 without bank approval.","Other amendments include deletion of Success Fee provisions and update of bank name to Banc of California."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193700,"accession_number":"0000950170-24-122244","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio Q3 net loss $30.5M; ADI-001 trial expanded to six autoimmune indications","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $30.5M ($0.34 per share) vs $49.9M ($1.16) in Q3 2023; cash $202.1M.","ADI-001 Phase 1 now covers LN, SLE, SSc, IIM, SPS, AAV; preliminary LN data expected 1H25.","FDA cleared IND amendment for ADI-001 in IIM and SPS in October 2024.","ADI-270 granted Fast Track for metastatic/advanced ccRCC; Phase 1 enrollment planned in Q4 2024.","Appointed Lloyd Klickstein, M.D., Ph.D. to Board of Directors in August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193699,"accession_number":"0000950170-24-114839","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-10-16T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adicet Bio receives FDA clearance to evaluate ADI-001 in IIM and Stiff Person Syndrome","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND amendment for ADI-001 to treat idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS).","Patient enrollment for IIM/SPS cohort expected to start Q1 2025; Phase 1 now covers six autoimmune diseases.","Phase 1 program has four arms: LN/SLE, SSc, AAV, and combined IIM/SPS cohort.","Initial clinical data from Phase 1 in autoimmune diseases expected first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210001,"accession_number":"0000950170-24-110166","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adicet opens Phase 1 enrollment for ADI-001 in autoimmune diseases; preliminary data expected H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial now enrolling lupus nephritis (LN) patients; SLE, SSc, AAV enrollment to open Q4 2024.","FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III/IV LN.","Plan to report preliminary clinical data in LN, SLE, SSc, and AAV by first half of 2025.","Trial has three arms: LN/SLE, SSc, AAV; single dose of ADI-001 with 28-day DLT window and 24-month follow-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210000,"accession_number":"0000950170-24-107988","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-09-19T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adicet ADI-001 shows robust tissue trafficking, complete B cell depletion in Phase 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean exposure of 236,701 CAR T cells per million in lymph node biopsies across all dose levels.","At 1E9 dose, 27-64% of total cellular material in evaluable biopsies, exceeding published autologous alpha-beta CAR T levels.","Complete CD19+ B cell depletion observed in secondary lymphoid tissue concurrent with trafficking and activation.","Data highlight potential best-in-class profile vs. anti-CD20 antibodies that failed to deplete B cells in tissues.","Initial clinical data from autoimmune programs (lupus nephritis, SLE, systemic sclerosis, AAV) expected H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209999,"accession_number":"0000950170-24-104915","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-09-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Adicet prioritizes ADI-001 for autoimmunity; closes MCL enrollment; reports 80% ORR, 60% CR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Focuses ADI-001 development on four autoimmune indications: lupus nephritis, SLE, systemic sclerosis, ANCA vasculitis.","Closed Phase 1 MCL enrollment; topline results: ORR 80% (8/10), CR 60% (6/10), median CR duration 17.5 months as of Aug 22, 2024.","Patients heavily pretreated (median 3 prior therapies); 30% had progressed on prior CAR T; no GvHD, low grade ≥3 CRS/neurotoxicity.","Plans to present translational data from Phase 1 NHL study at CAR-TCR Summit on Sept 19, 2024 in Boston.","Expects to expand ADI-001 clinical development into additional autoimmune indications near term."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209998,"accession_number":"0000950170-24-098485","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Adicet Bio appoints Dr. Lloyd Klickstein to its Board, effective August 19, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Michael Kauffman resigned from Board and Nominating Committee effective Aug 19, 2024; no disagreement cited.","Dr. Lloyd Klickstein, M.D., Ph.D., appointed as Class III director and to Nominating Committee; term through 2027 annual meeting.","Klickstein received an option for 70,200 shares, vesting over 36 months, plus standard non-employee director compensation.","Klickstein previously served as Adicet's Chief Innovation Officer and has leadership experience at Novartis and Eli Lilly."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209997,"accession_number":"0000950170-24-095744","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio Q2 net loss $29.9M; expands ADI-001 into three more autoimmune indications","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.9M ($0.33/share) vs $32.4M ($0.75) in Q2 2023; cash $224.1M, sufficient into H2 2026.","FDA cleared IND for ADI-001 in SLE, SSc, AAV; Fast Track for LN; enrollment starts Q3 2024 with data H1 2025.","FDA cleared IND for ADI-270 in RCC with Fast Track Designation; Phase 1 to start Q4 2024, data H1 2025.","R&D expenses $25.9M, down from $28.4M; G&A $6.9M, up from $6.5M.","MCL enrollment ongoing in ADI-001 Phase 1 GLEAN study; clinical update Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209996,"accession_number":"0000950170-24-081943","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adicet Bio receives FDA Fast Track Designation for ADI-270 in advanced kidney cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ADI-270 granted Fast Track Designation for metastatic/advanced clear cell RCC after checkpoint and VEGF inhibitor therapy.","This is Adicet's first gamma delta 1 CAR T cell therapy candidate to enter clinical trials for solid tumors.","ccRCC is the most common type of kidney cancer; Fast Track aims to expedite development and review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228212,"accession_number":"0000950170-24-076460","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adicet Bio receives FDA clearance for ADI-270 IND in renal cell carcinoma; Phase 1 trial planned for H2 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ADI-270 is the first gamma delta 1 CAR T cell therapy to enter clinical trials for solid tumors.","Phase 1 multicenter, open-label trial in relapsed/refractory clear cell RCC to start in H2 2024; preliminary data expected H1 2025.","ADI-270 is an armored allogeneic off-the-shelf CAR T targeting CD70+ cancers designed for high specificity and tumor infiltration.","Trial will evaluate safety, tolerability, pharmacokinetics, overall response rate, duration of response, and disease control rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228211,"accession_number":"0000950170-24-070568","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Adicet Bio stockholders approve doubling authorized shares to 300M and 5M share plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 150M to 300M via charter amendment; filed June 6.","2018 Stock Plan increased by 5M shares to 16.6M total; approved with 28.9M votes for.","Contingent option grants become effective: CEO Chen Schor receives 1.77M options; CFO Nick Harvey 375k; total 3.3M across management.","Charter amendment adopted to limit officer liability as permitted by Delaware law."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228210,"accession_number":"0000950170-24-069067","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adicet Bio gets FDA Fast Track for ADI-001 in lupus nephritis; Phase 1 starts this month","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation for ADI-001 in relapsed/refractory class III or IV lupus nephritis.","Company plans to initiate Phase 1 clinical study in lupus nephritis in June 2024.","ADI-001 previously showed CD19+ B-cell depletion in non-Hodgkin's lymphoma, similar to CAR T data in autoimmune diseases.","CEO Chen Schor cites urgent unmet need and plans to expand autoimmune program beyond lupus nephritis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228209,"accession_number":"0000950170-24-059496","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio Q1 2024 net loss $28.0M; on track for lupus nephritis trial and ADI-270 IND","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.0M ($0.35 per share) vs $30.9M ($0.72 per share) in Q1 2023.","Cash and equivalents $247.6M as of March 31, 2024; expected runway into H2 2026.","On track to initiate Phase 1 of ADI-001 in lupus nephritis in Q2 2024; data expected Q4 2024 or Q1 2025.","Preclinical data for ADI-270 presented at ASGCT; IND for renal cell carcinoma planned Q2 2024.","Enrolling MCL patients in ADI-001 GLEAN study; clinical update with 6-month data expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228208,"accession_number":"0000950170-24-057429","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Adicet presents ADI-270 preclinical data at ASGCT; IND filing expected Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADI-270 is an allogeneic anti-CD70 CAR γδ T cell therapy for solid and hematological cancers.","Preclinical data showed potent regression in ccRCC xenografts and lower CRS potential vs αβ CAR-T.","Armoring includes TGFβ receptor II inactivation and protection against alloreactive T cells.","IND submission in clear cell renal cell carcinoma (ccRCC) expected Q2 2024.","ADI-270 demonstrated both CAR-dependent and CAR-independent tumor targeting mechanisms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228207,"accession_number":"0000950170-24-046459","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Adicet reports preclinical data for ADI-270, on track for IND filing in Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADI-270 demonstrated robust anti-tumor activity in multiple CD70+ solid and hematological cancer models.","Preclinical data selected for oral presentation at ASGCT on May 10, 2024 in Baltimore.","ADI-270 uses CD27-based targeting and armored design to counteract tumor microenvironment and host T-cell clearance.","Company confirms IND submission for renal cell carcinoma remains on track for Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246960,"accession_number":"0000950170-24-035366","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Adicet Bio enters into ATM equity offering agreement with Jefferies LLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement allows sale of common stock from time to time through Jefferies as agent or principal.","Jefferies to receive 3.0% of gross proceeds from shares sold under the ATM program.","Shares will be issued under existing shelf registration statement (S-3) and a prospectus supplement filed March 22, 2024.","Either party may terminate the agreement at any time upon written notice; no minimum sale obligation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246959,"accession_number":"0000950170-24-033476","cik":1720580,"company_name":"Adicet Bio, Inc.","ticker":"ACET","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Adicet Bio reports Q4 net loss $29.5M, extends cash runway into 2H 2026; IND cleared for ADI-001 in lupus nephritis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.5M ($0.69/share) in Q4 2023 vs $29.9M ($0.72/share) in Q4 2022; full-year net loss $142.7M ($3.31/share) vs $69.8M ($1.70/share).","Cash and equivalents $159.7M at Dec 31, 2023; raised net $91.8M from public offering and $19.3M from ATM in Jan 2024, extending runway into 2H 2026.","FDA cleared IND for ADI-001 in lupus nephritis in Dec 2023; Phase 1 trial initiation expected in Q2 2024 with preliminary data in Q4 2024/Q1 2025.","On track to file IND for ADI-270 in renal cell carcinoma in Q2 2024; Phase 1 clinical data expected in first half of 2025.","Appointed Benjamin Hsu, M.D., Ph.D., as VP Clinical Development - Autoimmune, to lead autoimmune cell therapy programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":79646971.72235294,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}